GSK at ESMO 2026

Oct 23–27, 2026 Madrid, Spain ~37k attendees Website

GSK takes part in 3 sessions at ESMO 2026 in Madrid, and exhibits at Booth 1023. Its program centres on endometrial and ovarian cancer, including long-term survival results in advanced endometrial cancer and the role of antibody-drug conjugates. It also covers digital twins of biology and predictive modelling in cancer drug discovery.

OrganizationESMO 2026 Attendance
gsk.com
Large pharmaExhibitor
British pharmaceutical company whose oncology medicines include niraparib, dostarlimab and momelotinib.
Booth
Exhibiting at Booth 1023
Satellite
Fri Oct 23
18:15–19:45
GSK - From evidence to clinical practice: Long-term survival outcomes in advanced endometrial cancer
Sponsored session · with NYU Langone Perlmutter Cancer Center
Gynaecological cancers
Satellite
Sat Oct 24
13:00–14:30
GSK - From Discovery to Impact: ADCs in Endometrial and Ovarian Cancer Care
Sponsored session · with Hospital Universitario Puerta de Hierro Majadahonda
Gynaecological cancers
Talk
Mon Oct 26
10:55–11:15
Digital biology twins and predictive oncology in drug discovery and development
Digital health and AI in oncology: Transforming patient monitoring and care

Explore the full ESMO 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Madrid. Leave your work email and we’ll be in touch.

Privacy

Download the full ESMO 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from GSK

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction